Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026)

Annexon's (ANNX) quarterly Liabilities and Shareholders Equity came in at $262.9 million in Q1 2026, down 13.25% year-on-year from $303.0 million in Q1 2025, and down 5.29% quarter-over-quarter from $277.6 million in Q4 2025.

Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Annexon's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $262.9 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 13.25% year-over-year to $262.9 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 28.08% decrease from a year earlier, with the FY2025 full-year figure at $277.6 million, down 20.71% from the prior year.
  • Liabilities and Shareholders Equity slipped to $262.9 million in Q1 2026 per ANNX's latest filing, from $277.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $406.1 million in Q2 2024 and bottomed at $203.8 million in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $277.6 million (2025), against an average of $285.2 million.
  • Across the five-year window, Liabilities and Shareholders Equity jumped 85.84% in 2024 and slumped 39.5% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $285.1 million in 2022, then increased by 4.41% to $297.7 million in 2023, then grew by 17.6% to $350.1 million in 2024, then slipped by 20.71% to $277.6 million in 2025, then slipped by 5.29% to $262.9 million in 2026.
  • Per Business Quant, the three latest ANNX Liabilities and Shareholders Equity figures stand at $262.9 million (Q1 2026), $277.6 million (Q4 2025), and $229.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Annexon 1.03 Bn 804.24 Mn - 262.89 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 262.89 Mn
Dec 31, 2025 277.57 Mn
Sep 30, 2025 229.14 Mn
Jun 30, 2025 264.57 Mn
Mar 31, 2025 303.03 Mn
Dec 31, 2024 350.07 Mn
Sep 30, 2024 378.78 Mn
Jun 30, 2024 406.09 Mn
Mar 31, 2024 304.07 Mn
Dec 31, 2023 297.67 Mn
Sep 30, 2023 203.82 Mn
Jun 30, 2023 233.01 Mn
Mar 31, 2023 268.78 Mn
Dec 31, 2022 285.10 Mn
Sep 30, 2022 312.72 Mn
Jun 30, 2022 220.70 Mn
Mar 31, 2022 250.57 Mn
Dec 31, 2021 287.04 Mn
Sep 30, 2021 310.16 Mn
Jun 30, 2021 331.78 Mn